From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
American Journal of Health-System Pharmacy · 05.12.2024 · 81 (24) · 1245-1251
DOI: 10.1093/ajhp/zxae183 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 04.07.2024. Verfasst von Kristie M Walenczyk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Purpose
Compared to estimated population prevalence rates, relatively few patients at risk are diagnosed with and treated for transthyretin cardiac amyloidosis (ATTR-CA). Where along the clinical pathway patient drop-off occurs, as well as the association of drop-off with patient sociodemographic characteristics, remains unknown.
Methods
Using data from a healthcare system–wide cardiovascular imaging repository and specialty pharmacy, we characterized the clinical pathway from diagnosis with pyrophosphate scintigraphy (PYP) to tafamidis prescription, initiation, and adherence. Standardized differences (d values of ≥0.20, indicating at least a small effect size) were used to compare sociodemographics (age, sex, race, Area Deprivation Index) among patients with PYP-identified ATTR-CA by tafamidis prescription status and among patients prescribed tafamidis by initiation status. Tafamidis adherence was measured with the proportion of days covered (PDC).
Results
Of 97 patients with ATTR-CA, 58.8% were prescribed tafamidis, with 80.7% of those initiating therapy. Patients with ATTR-CA prescribed tafamidis were younger than those not prescribed tafamidis (d = –0.30). Utilization of a specialty pharmacy resulted in enrichment of treatment in subgroups traditionally undertreated in cardiovascular medicine, with higher rates of tafamidis initiation among women (100% initiation), patients of Black/African American race (d = 0.40), and those living in more economically disadvantaged areas (d ≥ 0.30). Adherence was high (PDC of >80%) in 88.4% of those initiating tafamidis.
Conclusion
These findings highlight the tremendous opportunity for more robust ATTR-CA clinical programs, identifying potential patient subgroups that should be targeted to reduce disparities. For patients diagnosed with ATTR-CA, utilization of a specialty pharmacy process appears to ensure equitable provision of tafamidis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
- Department of Psychology, VA Connecticut Healthcare System, West Haven, CT, USA.
- Section of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Clinical Pharmacy Services, Yale New Haven Health, New Haven, CT, USA.
- Department of Cardiology, VA Connecticut Healthcare System, West Haven, CT, USA.
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Zitieren
APA
Walenczyk, K. M., Singh, A., Tong, K., Burg, M. M., & Miller, E. J. (2024). From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal of Health-System Pharmacy, 81(24), 1245-1251. https://doi.org/10.1093/ajhp/zxae183
Vancouver
Walenczyk KM, Singh A, Tong K, Burg MM, Miller EJ. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal of Health-System Pharmacy. 2024;81(24):1245-1251. doi:10.1093/ajhp/zxae183
BibTeX
@article{Walenczyk2024,
author = {Walenczyk, Kristie M and Singh, Avinainder and Tong, Kimhouy and Burg, Matthew M and Miller, Edward J},
title = {From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics},
journal = {American Journal of Health-System Pharmacy},
year = {2024},
volume = {81},
number = {24},
pages = {1245--1251},
doi = {10.1093/ajhp/zxae183}
}
EUVIMED